Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 4/20 | 0.68 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271295 | 0.92 | LGMN (0.71) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL18780269 | 0.91 | LGMN (0.70) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL13938880 | 0.91 | LGMN (0.78) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL12022464 | 0.91 | LGMN (0.78) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL13938893 | 0.90 | LGMN (0.79) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL12022495 | 0.90 | LGMN (0.79) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL12022476 | 0.90 | LGMN (0.82) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL18717385 | 0.90 | LGMN (0.69) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL18717386 | 0.88 | LGMN (0.67) | LGMNCTSLCTSKCTSBCTSS | |
| SCHEMBL16421523 | 0.88 | LGMN (0.67) | LGMNCTSLCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058177-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | THE SCRIPPS RESEARCH INSTITUTE | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058177-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | LGMN, LNPEP, CLTA | LGMN 1/4885CTSL 258/4885CTSK 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.